-
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and...
IN THE SPOTLIGHT
-
Taletrectinib Approved for Locally Advanced and Metastatic NSCLC with ROS1 Rearrangements
On June 11, 2025, the US Food and Drug Administration (FDA) announced the approval of taletrectinib (Ibtrozi™) to treat patients with locally advanced or metastatic non-small cell... -
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue... -
New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non... -
The Promise of PROTACs for Treating RET+ Lung Cancer
RET proteins are a type of receptor tyrosine kinase—an important group of signaling molecules in healthy cells. When RET proteins are turned “on” and “off” in healthy cells, they... -
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with... -
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and... -
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery... -
Protein Degraders in Cancer Treatment: What They Are and How They Work
Join us for an engaging Facebook Live discussion on the role of RET gene alterations (fusions and mutations) in cancers such as lung and thyroid cancer. While current therapies... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Advances in NSCLC Bring Excitement in the Lung Space; According to Jorge Nieva, MD, there are a multitude of things that can be explored to...
Advances in NSCLC Bring Excitement in the Lung Space; According to Jorge Nieva, MD, there are a multitude of things that can be explored to...
Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC: An Explorative Experience
Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC: An Explorative Experience
Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib
COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib
Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database
Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database
Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC
PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience
PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience
China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis
Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC
Taletrectinib Approved for Locally Advanced and Metastatic NSCLC with ROS1 Rearrangements
Taletrectinib Approved for Locally Advanced and Metastatic NSCLC with ROS1 Rearrangements
On June 11, 2025, the US Food and Drug Administration (FDA) announced the approval of taletrectinib (Ibtrozi™) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 rearrangements. Taletrectinib is a next-generation, highly specific kinase inhibitor of ROS1 that was designed to treat ROS1+ NSCLC in patients whose tumors have developed drug resistance to previous targeted therapies as well as a first treatment option for newly diagnosed patients…
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
New Treatment Approved for NSCLC with High Level of c-Met Protein
New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with high levels of c-Met protein who have been previously treated with a systemic therapy, such as immunotherapy or chemotherapy. This ADC, or antibody-drug conjugate, is the first approval of its kind. This ADC treatment is designed with two key elements. One part of the…
The Promise of PROTACs for Treating RET+ Lung Cancer
The Promise of PROTACs for Treating RET+ Lung Cancer
RET proteins are a type of receptor tyrosine kinase—an important group of signaling molecules in healthy cells. When RET proteins are turned “on” and “off” in healthy cells, they control the function of other proteins. This cascading effect allows the cells to manage important cellular functions such as cell growth through protein signaling pathways. When specific changes (such as mutations or fusions) occur in RET proteins, they can become hyperactive, disrupting many important…
Watch HOPE Summit Videos
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and immunotherapy. Now, we are seeing the emergence of another class of lung cancer treatments called antibody-drug conjugates (ADCs), that are a combination of targeted therapy and chemotherapy.ADCs act like a “smart chemotherapy” that aim to deliver the drug compound directly to cancer cells, reducing harm to healthy tissue.As…
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery, or immunotherapy. Integrative oncology—also called integrative medicine—is an evidence-informed whole-body approach to health. It is often used to address symptoms and side effects caused by disease or treatment and improve overall quality of life. Specific examples of integrative oncology for lung cancer…
What Should Patients Know About Lung Cancer Surgery?
What Should Patients Know About Lung Cancer Surgery?
Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non-small cell lung cancer (NSCLC) staged at I, II, or IIIA. Surgery is rarely considered for tumors at stage IIIB or IV because those lung cancers have spread to other parts of the body. It is also rarely used to treat small cell lung cancer (SCLC) because SCLC is typically diagnosed at a later stage. Types of…
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…
Protein Degraders in Cancer Treatment: What They Are and How They Work
Protein Degraders in Cancer Treatment: What They Are and How They Work
Join us for an engaging Facebook Live discussion on the role of RET gene alterations (fusions and mutations) in cancers such as lung and thyroid cancer.While current therapies, including tyrosine kinase inhibitors, are a cornerstone in treatment, there's a growing need for new solutions when these drugs lose their effectiveness. In this session, we will hear from Emily Walthall and Dr. Hilary Hammell from the RETpositive community as they share their insights and experiences.Also joining us is…
RET-Positive Lung Cancer: New Treatments and Beyond
RET-Positive Lung Cancer: New Treatments and Beyond
The four-person panel, including John Heymach, MD, PhD, from MD Anderson Cancer Center, discuss the current FDA-approved targeted treatments for RET-positive lung cancer—selpercatinib (Retevmo) and pralsetinib (Gavreto). While these first-line treatments have proven helpful in treating RET-positive non-small cell lung cancer, the cancer cells can eventually become resistant to the treatment, which is guiding much of Dr. Heymach’s attention at the moment.Watch the full video to hear about:Dr.…
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
On the West Coast, wildfires are taking human lives and destroying homes. On the East Coast, the devastating results of Hurricane Helene are leading to illegal open burning of debris and trash. Thousands of miles separate these fires, but the results are the same—dangerous particles are entering the air we breathe. LUNGevity spoke with Angela Hopper, an 11-year lung cancer survivor who spent 30 years working as an air quality specialist at the North Carolina Department of Environmental…
Have You Heard About Cancer Cachexia?
Have You Heard About Cancer Cachexia?
Cachexia is a complex condition that causes severe muscle and weight loss, physical inactivity, and metabolic disruptions such as fatigue, nausea, and loss of concentration. It's estimated that 50% of individuals with lung cancer experience cachexia at some point.Learn more about cachexia and how to recognize the symptoms.
Conversations that Count: Understanding the Complexities of Race and Health
Conversations that Count: Understanding the Complexities of Race and Health
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In January, we welcomed Matthew McCurdy, MPH, co-founder and executive director of BLKHLTH, to speak on the complexities of race and…
Real-World Examples of Patient Involvement in Designing Clinical Trials
Real-World Examples of Patient Involvement in Designing Clinical Trials
Read time: 2 minutes.Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can…
Developing Clinical Trials that Account for the Realities of Patient Life
Developing Clinical Trials that Account for the Realities of Patient Life
Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients…
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Read time: 6 minutes. After a few unimpressive encounters I experienced in real life, I tentatively returned to the Match dating app. That’s where I stumbled upon a very sweet, kind-hearted, nerdy, and compassionate man. Then I met Nate (Ha! Just joking). It was Nate. We bonded so quickly during which we identified our life goals. One goal was to have a family. Yes, we did the whole “let’s get ready” experience. We invested in a new SUV. We were eyeing new housing…
The 5 Most Popular Lung Cancer Blogs From 2024
The 5 Most Popular Lung Cancer Blogs From 2024
Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of…